Optimizing drug discovery by investigative toxicology

Current and future trends

Mario Beilmann, Harrie Boonen, Andreas Czich, Gordon Dear, Philip Hewitt, Tomas Mow, Peter Newham, Teija Oinonen, Francois Pognan, Adrian Roth, Jean Pierre Valentin, Freddy Van Goethem, Richard J. Weaver, Barbara Birk, Scott Boyer, Francesca Caloni, Alice E. Chen, Raffaella Corvi, Mark T.D. Cronin, Mardas Daneshian & 14 others Lorna C. Ewart, Rex E. FitzGerald, Geraldine A. Hamilton, Thomas Hartung, Joshua D. Kangas, Nynke I. Kramer, Marcel Leist, Uwe Marx, Sebastian Polak, Costanza Rovida, Emanuela Testai, Bob Van de Water, Paul Vulto, Thomas Steger-Hartmann

Research output: Contribution to journalArticle

Abstract

Investigative toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, investigative toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adherence to the 3R (Replacement, Reduction, and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, investigative toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of investigative toxicology is to improve preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded owing to the use of inappropriate animal models. Progress in investigative toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field, a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive, and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an “Investigative Toxicology Think Tank”, which aimed to enhance interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights investigative toxicology’s position by identifying key challenges and perspectives.

Original languageEnglish (US)
Pages (from-to)289-313
Number of pages25
JournalALTEX
Volume36
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug Discovery
Toxicology
Drug Industry
Animal Testing Alternatives
Safety
Animal Welfare
Systems Analysis
Computer Simulation
Animal Models
Technology
Education
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pharmacology
  • Medical Laboratory Technology

Cite this

Beilmann, M., Boonen, H., Czich, A., Dear, G., Hewitt, P., Mow, T., ... Steger-Hartmann, T. (2019). Optimizing drug discovery by investigative toxicology: Current and future trends. ALTEX, 36(2), 289-313. https://doi.org/10.14573/altex.1808181

Optimizing drug discovery by investigative toxicology : Current and future trends. / Beilmann, Mario; Boonen, Harrie; Czich, Andreas; Dear, Gordon; Hewitt, Philip; Mow, Tomas; Newham, Peter; Oinonen, Teija; Pognan, Francois; Roth, Adrian; Valentin, Jean Pierre; Van Goethem, Freddy; Weaver, Richard J.; Birk, Barbara; Boyer, Scott; Caloni, Francesca; Chen, Alice E.; Corvi, Raffaella; Cronin, Mark T.D.; Daneshian, Mardas; Ewart, Lorna C.; FitzGerald, Rex E.; Hamilton, Geraldine A.; Hartung, Thomas; Kangas, Joshua D.; Kramer, Nynke I.; Leist, Marcel; Marx, Uwe; Polak, Sebastian; Rovida, Costanza; Testai, Emanuela; Van de Water, Bob; Vulto, Paul; Steger-Hartmann, Thomas.

In: ALTEX, Vol. 36, No. 2, 01.01.2019, p. 289-313.

Research output: Contribution to journalArticle

Beilmann, M, Boonen, H, Czich, A, Dear, G, Hewitt, P, Mow, T, Newham, P, Oinonen, T, Pognan, F, Roth, A, Valentin, JP, Van Goethem, F, Weaver, RJ, Birk, B, Boyer, S, Caloni, F, Chen, AE, Corvi, R, Cronin, MTD, Daneshian, M, Ewart, LC, FitzGerald, RE, Hamilton, GA, Hartung, T, Kangas, JD, Kramer, NI, Leist, M, Marx, U, Polak, S, Rovida, C, Testai, E, Van de Water, B, Vulto, P & Steger-Hartmann, T 2019, 'Optimizing drug discovery by investigative toxicology: Current and future trends', ALTEX, vol. 36, no. 2, pp. 289-313. https://doi.org/10.14573/altex.1808181
Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T et al. Optimizing drug discovery by investigative toxicology: Current and future trends. ALTEX. 2019 Jan 1;36(2):289-313. https://doi.org/10.14573/altex.1808181
Beilmann, Mario ; Boonen, Harrie ; Czich, Andreas ; Dear, Gordon ; Hewitt, Philip ; Mow, Tomas ; Newham, Peter ; Oinonen, Teija ; Pognan, Francois ; Roth, Adrian ; Valentin, Jean Pierre ; Van Goethem, Freddy ; Weaver, Richard J. ; Birk, Barbara ; Boyer, Scott ; Caloni, Francesca ; Chen, Alice E. ; Corvi, Raffaella ; Cronin, Mark T.D. ; Daneshian, Mardas ; Ewart, Lorna C. ; FitzGerald, Rex E. ; Hamilton, Geraldine A. ; Hartung, Thomas ; Kangas, Joshua D. ; Kramer, Nynke I. ; Leist, Marcel ; Marx, Uwe ; Polak, Sebastian ; Rovida, Costanza ; Testai, Emanuela ; Van de Water, Bob ; Vulto, Paul ; Steger-Hartmann, Thomas. / Optimizing drug discovery by investigative toxicology : Current and future trends. In: ALTEX. 2019 ; Vol. 36, No. 2. pp. 289-313.
@article{8bd4aa02220c4114abd96abb1de043d6,
title = "Optimizing drug discovery by investigative toxicology: Current and future trends",
abstract = "Investigative toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, investigative toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adherence to the 3R (Replacement, Reduction, and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, investigative toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of investigative toxicology is to improve preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded owing to the use of inappropriate animal models. Progress in investigative toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field, a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive, and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an “Investigative Toxicology Think Tank”, which aimed to enhance interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights investigative toxicology’s position by identifying key challenges and perspectives.",
author = "Mario Beilmann and Harrie Boonen and Andreas Czich and Gordon Dear and Philip Hewitt and Tomas Mow and Peter Newham and Teija Oinonen and Francois Pognan and Adrian Roth and Valentin, {Jean Pierre} and {Van Goethem}, Freddy and Weaver, {Richard J.} and Barbara Birk and Scott Boyer and Francesca Caloni and Chen, {Alice E.} and Raffaella Corvi and Cronin, {Mark T.D.} and Mardas Daneshian and Ewart, {Lorna C.} and FitzGerald, {Rex E.} and Hamilton, {Geraldine A.} and Thomas Hartung and Kangas, {Joshua D.} and Kramer, {Nynke I.} and Marcel Leist and Uwe Marx and Sebastian Polak and Costanza Rovida and Emanuela Testai and {Van de Water}, Bob and Paul Vulto and Thomas Steger-Hartmann",
year = "2019",
month = "1",
day = "1",
doi = "10.14573/altex.1808181",
language = "English (US)",
volume = "36",
pages = "289--313",
journal = "ALTEX : Alternativen zu Tierexperimenten",
issn = "1868-596X",
publisher = "Elsevier GmbH",
number = "2",

}

TY - JOUR

T1 - Optimizing drug discovery by investigative toxicology

T2 - Current and future trends

AU - Beilmann, Mario

AU - Boonen, Harrie

AU - Czich, Andreas

AU - Dear, Gordon

AU - Hewitt, Philip

AU - Mow, Tomas

AU - Newham, Peter

AU - Oinonen, Teija

AU - Pognan, Francois

AU - Roth, Adrian

AU - Valentin, Jean Pierre

AU - Van Goethem, Freddy

AU - Weaver, Richard J.

AU - Birk, Barbara

AU - Boyer, Scott

AU - Caloni, Francesca

AU - Chen, Alice E.

AU - Corvi, Raffaella

AU - Cronin, Mark T.D.

AU - Daneshian, Mardas

AU - Ewart, Lorna C.

AU - FitzGerald, Rex E.

AU - Hamilton, Geraldine A.

AU - Hartung, Thomas

AU - Kangas, Joshua D.

AU - Kramer, Nynke I.

AU - Leist, Marcel

AU - Marx, Uwe

AU - Polak, Sebastian

AU - Rovida, Costanza

AU - Testai, Emanuela

AU - Van de Water, Bob

AU - Vulto, Paul

AU - Steger-Hartmann, Thomas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Investigative toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, investigative toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adherence to the 3R (Replacement, Reduction, and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, investigative toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of investigative toxicology is to improve preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded owing to the use of inappropriate animal models. Progress in investigative toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field, a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive, and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an “Investigative Toxicology Think Tank”, which aimed to enhance interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights investigative toxicology’s position by identifying key challenges and perspectives.

AB - Investigative toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, investigative toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adherence to the 3R (Replacement, Reduction, and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, investigative toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of investigative toxicology is to improve preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded owing to the use of inappropriate animal models. Progress in investigative toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field, a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive, and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an “Investigative Toxicology Think Tank”, which aimed to enhance interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights investigative toxicology’s position by identifying key challenges and perspectives.

UR - http://www.scopus.com/inward/record.url?scp=85066157984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066157984&partnerID=8YFLogxK

U2 - 10.14573/altex.1808181

DO - 10.14573/altex.1808181

M3 - Article

VL - 36

SP - 289

EP - 313

JO - ALTEX : Alternativen zu Tierexperimenten

JF - ALTEX : Alternativen zu Tierexperimenten

SN - 1868-596X

IS - 2

ER -